Applications

1625 – Dinutuximab beta for high-risk neuroblastoma

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

Health technology assessment.

Service or technology in this application

Dinutuximab beta is indicated for the treatment of high-risk neuroblastoma in patients who have previously received induction chemotherapy and achieved at least a partial response. Dinutuximab beta is an antibody directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells. After binding, dinutuximab beta induces cell death through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity.

Type: Therapeutic

Medical condition this application addresses

Neuroblastoma is an embryonal tumour of the autonomic nervous system and usually occurs in young children. The tumours are found in sympathetic nervous system tissues, typically in the adrenal medulla or paraspinal ganglia and can present as mass lesions in the neck, chest, abdomen, or pelvis.

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: 12 June 2020
  • MSAC meeting: 28 to 29 July 2020